The global breast cancer brachytherapy market size is estimated to reach USD 1.3 billion by 2030, expanding at a CAGR of 6.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of breast cancer is expected to accelerate market growth. For instance, the Breastcancer.org reported that as of January 2020, there were more than 3.5 million women suffering from breast cancer in the U.S.
In addition, the rising adoption of brachytherapy by academic medical centers, oncology centers, and hospitals is expected to boost the market growth. For instance, in October 2018, Navicent Health adopted the Xoft Axxent Electronic Brachytherapy (eBx) System developed by iCAD, Inc. for the treatment of breast cancer in Georgia. Furthermore, in October 2018, SUNY Upstate Medical University also adopted the Xoft Axxent Electronic Brachytherapy (eBx) System to provide treatment for early-stage breast cancer.
Moreover, government hospitals in developing countries are installing advanced systems to provide better quality treatment for their patients. For instance, in August 2018, Eckert and Ziegler BEBIG delivered and installed SagiNova HDR afterloader at BP Koirala Memorial Cancer Hospital of Nepal. SagiNova is suitable for interstitial breast implants. Hence, the use of such brachytherapy systems by hospitals is expected to fuel market growth.
Market players entering into strategic initiatives such as collaborations and partnerships are anticipated to propel the demand over the next few years. For instance, in July 2018, RaySearch partnered with Eckert and Ziegler BEBIG to integrate SagiNova with the RayCare oncology information system and RayStation treatment planning system to improve treatment outcomes during brachytherapy.
An increase in funding initiatives for HDR units in medical centers by organizations is estimated to drive the market. For instance, in April 2019, OSJ Charities Trust Fund collaborated with the National Federation of Italian Canadians to donate SagiNova for Santo Spirito Hospital as an alternative to external beam radiation therapy for a targeted approach and shorter treatment time.
Favorable reimbursement policies for oncologists, surgeons, and hospitals are expected to fuel market growth. For instance, HDR brachytherapy offers USD 11,000 as Medicare reimbursement for five days treatment period according to the coding issued by Centers for Medicare and Medicaid Services (CMS).
Request a free sample copy or view report summary: Breast Cancer Brachytherapy Market Report
HDR brachytherapy dominated the market in 2024 and is also projected to be the fastest-growing technology segment over the forecast period
Factors such as rapid delivery of radiation, accuracy, and precise tumor-specific dose delivery in a shorter period of time are expected to drive the segment
North America has dominated the market in 2024 owing to the presence of key players and increasing adoption of the therapy by oncology centers and hospitals
In Asia Pacific, the market is estimated to grow fast over the forecast period due to high unmet needs and growth opportunities for investors and companies to expand their presence in the region.
Grand View Research has segmented the global breast cancer brachytherapy market based on technology, product, and region:
Breast Cancer Brachytherapy Technology Outlook (Revenue, USD Million, 2018 - 2030)
High Dose Rate (HDR)
Low Dose Rate (LDR)
Breast Cancer Brachytherapy Product Outlook (Revenue, USD Million, 2018 - 2030)
Applicators and Afterloaders
Electronic Brachytherapy
Others
Breast Cancer Brachytherapy Regional Outlook (Revenue, USD Billion, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in Breast Cancer Brachytherapy Market
Eckert & Ziegler BEBIG
Elekta
Varian Medical Systems, Inc.
Hologic, Inc.
Merit Medical Systems
BD
"The quality of research they have done for us has been excellent..."